Shares in Sarepta reversed some of their recent declines after the FDA added a warning label to its Duchenne muscular dystrophy (DMD) gene therapy, ending a protracted period of uncertainty for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback